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concomitant management of medication-related osteonecrosis of 
the jaw: A case report 
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a Thomas Jefferson University Hospital, Department of Oral and Maxillofacial Surgery, Philadelphia, PA, USA 
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1. Introduction 
The first description of medication-related osteonecrosis of the jaw (MRONJ) associated with bisphosphonates was published by 
Marx in 2003 [1]. MRONJ is defined as bone exposed to the oral cavity for at least eight weeks in the maxillofacial region for at least 8 
weeks in patients at-risk due to prior or current medication therapy. Over the years, additional medications have been implicated 
MRONJ beyond bisphosphonates and interdisciplinary strategies for screening and management have shown a reduction in the rate of 
MRONJ [2]. Despite the increased attention and research, the pathophysiology of MRONJ remains poorly understood. Most cases and 
reviews published thus far have occurred in patients previously diagnosed with malignant and metastatic disease as bisphosphonate 
use in these patients reduces the risk of adverse skeletal events such as fractures [3]. We present a case where treatment of MRONJ 
based on clinical parameters resulted in a subsequent diagnosis of occult B-cell lymphoproliferative disorder. 
2. Case report 
A 79-year-old female presented to the Department of Oral & Maxillofacial Surgery for evaluation of a lesion of the anterior 
mandible. The patient reported history of non-insulin dependent diabetes mellitus, hypertension, hyperlipidemia, and osteoporosis. 
Her osteoporosis was treated by her primary care physician with alendronate 70mg weekly for a total duration of five years. Her 
diabetes was well controlled and she denied history of tobacco use or smoking. She reported dental extractions two years prior to 
facilitate the fabrication of a complete mandibular denture. Seven months prior to her presentation to our clinic, she developed a large 
submandibular swelling which resulted in spontaneous submental drainage. She reported she was only treated with antibiotics and the 
swelling resolved with persistent drainage at a submental site. For the seven months since her infection and initial drainage, she 
reported persistent drainage of fluid from underneath her chin for which she would use gauze dressings as needed. She denied recent 
fever, chills, nausea, vomiting, difficulty breathing, or dysphagia. 
On clinical exam, she was normocephalic with no appreciable facial asymmetry. In the submental region, she had a slight non- 
tender swelling with a noted depression associated with granulation tissue (Fig. 1a). The granulation tissue was associated with a 
chronic fistula which had minimal seropurulent drainage. Intraorally, she was completely edentulous on the maxilla and mandible. She 
had no swelling of the floor of mouth or posteriorly towards the oropharynx. On the lingual aspect of the left mandible, there was an 
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area of exposed bone 1cm by 1cm in dimension (Fig. 1b). On the right mandible, there were punctate fistula with seropurulent 
drainage (Fig. 1c). At that time, cultures were taken of the drainage intraorally and extraorally. A CT Maxillofacial was performed 
which demonstrated multiple areas of bone erosion involving both sides of the mandible. The erosion of the left mandible was greater 
than right and there was associated cortical destruction with surrounding sclerosis of the adjacent bone without periosteal reaction. 
Additionally, there was a linear sequestration along the medial aspect of the left body of mandible (Fig. 2). Based on her history and 
clinical presentation, she was given a diagnosis of Stage III MRONJ. The patient was started on amoxicillin/clavulanic acid therapy and 
scheduled for surgical intervention. The cultures returned from the extraoral and intraoral sites were both polymicrobial in nature 
representing skin and oral flora respectively. Ultimately, the patient was taken to the operating room where she had segmental 
resection of the involved portion of the anterior mandible with placement of custom designed patient specific plate for mandibular 
reconstruction (Fig. 3). Given the chronicity of the infection and the fistula, the decision was made not to attempt reconstruction of the 
area with bone graft at the same time as resection. She was admitted for inpatient management post-operatively. She was evaluated by 
the Department of Infectious Disease and a peripherally inserted central catheter was placed in anticipation of an extended duration of 
intravenous antibiotics. The cultures from surgery grew Enterobacter cloacae. She tolerated the procedure and was discharged to home 
two days after the procedure with intravenous ertapenem therapy for a planned 6-week duration. Histopathologic analysis performed 
on the resection specimen revealed viable and non-viable bone with an unanticipated finding of chronic plasmocytic infiltration. The 
specimen showed a predominantly plasmocytic inflammatory infiltrate arranged in “sheets” in some areas (Fig. 4). The increased 
number of plasma cells and their growth pattern was concerning for a plasma cell dyscrasia. In situ hybridization for kappa and lambda 
light chain was noncontributory due to prior decalcification of the specimen. The findings prompted referral to the Department of 
Hematology/Oncology for further workup. A full skeletal series and long bone survey was performed which revealed no lytic lesions. A 
complete blood count with differential was within normal limits. The beta-2 microglobulin was negative. SPEP demonstrated faint 
bands in IgG and lambda. The free light chain ratio was elevated in both the serum and urine analyses. The serum kappa/lambda ratio 
was high at 3.19 and the urine kappa/lambda ratio was 82.27. Ultimately, a bone marrow biopsy was performed. The core biopsy 
showed mild increase in small mature B-cells. Immunohistochemistry for CD20 and PAX-5 shows a predominance of B cells involving 
5–10% of marrow (Fig. 5). Concurrent flow cytometry detected an CD5/CD23  clonal B-cell population with kappa light chain 
restriction. This phenotype was consistent with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). A concurrent 
FISH study identified a deletion of RB1 and concurrent karyotype demonstrated no abnormalities (Fig. 6). The patient was ultimately 
diagnosed with CD5 B cell lymphoproliferative disorder. She continued active surveillance with oncology for transformation or 
change of disease. From a surgical standpoint, the patient healed without issue and demonstrated resolution of chronic infection and 
draining fistula post operatively (Figs. 7 and 8). 
3. Discussion 
Although MRONJ is related to antiresorptive therapy for many different diseases including blood dyscrasias, it is infrequently found 
concomitant with the disease process. There have been a few case reports of concurrent metastatic disease, including multiple 
myeloma and breast cancer, in resection specimens for MRONJ [4–6]. Carlson et al. [7] performed a large retrospective study to 
identify patients treated for MRONJ with resection on IV bisphosphonate therapy for cancer with metastatic disease found in the 
resection specimens. The prevalence of cancer detected in the MRONJ specimens of this group was 5.3%, with multiple myeloma as the 
predominant associated metastasis [7]. In the setting of cancer with metastases to bone and lytic lesions of multiple myeloma, IV 
bisphosphonate therapy is supported in various guidelines to reduce the rate of pathologic fractures and morbidity from interventions 
Fig. 1. Preoperative Photos A) Worms-eye view of orocutaneous fistula. B) Intraoral view of exposed bone on left mandible C) Intraoral view of 
orocutaneous fistula D) Patient provided photo of previous swelling months prior to presentation. 
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(caption on next page) 
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Fig. 2. Pre-operative radiographs. A CT maxillofacial bony window with representative axial (A), coronal (B), and sagittal cuts. D) Pano-
ramic radiograph. 
A)  B)
Fig. 3. Intraoperative photos of resected specimen from posterior (A) and superior (B) views.  
)B)A
Fig. 4. Histopathological evaluation with hematoxylin and eosin stains. A) Biopsy specimen showing necrotic bony trabeculae, with empty lacunae 
in the top of the frame compared with viable osteocytes in the lower right corner. B) Bone marrow core biopsy showing a lymphoid aggregate 
comprised of monomorphic population of small mature lymphocytes. Note trilineage hematopoiesismm in background (H&E, original magnifica-
tion 400). 
)B)A
Fig. 5. Immunohistochemical evaluation of bone marrow biopsy specimens. A) Pax-5 stain highlights B-cells in the interstitium and loose aggre-
gates in bone marrow core biopsy B) CD5 stain in the bone marrow core biopsy shows similar distribution to B-cells (original magnification 400). 
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for bone pain [3,8]. The current American Association of Oral and Maxillofacial Surgeons (AAOMS) position paper on MRONJ con-
siders the role of anti-angiogenic medications in disease progression in addition to anti-resorptive medications such as bisphospho-
nates [2]. Since the position paper update, there have been a few case reports of MRONJ from disease modifying antirheumatic drugs 
(DMARDs) and immunosuppressive medications used after organ transplant [9,10]. A recent case series demonstrates a case of MRONJ 
in the setting of treatment of chronic lymphocytic leukemia with antiresorptive agents and targeted therapy with tyrosine kinase 
inhibitors [11]. Aghaloo and Tetradis [12] reported a case series of six patients with MRONJ without antiangiogenic or antiresorptive 
medications, rather the use of various anti-rheumatic agents with Stage II and III MRONJ. 
Interestingly, methotrexate and rituximab are associated with iatrogenic lymphoproliferative disorders [13,14]. Our patient was 
ultimately diagnosed with a CD5 B cell lymphoproliferative disorder as she did not meet the diagnostic criteria for chronic lym-
phocytic leukemia and she demonstrated deletion of RB1, a frequent chromosomal abnormality found in B-cell lymphoproliferative 
disorders [15]. Her presentation was similar to monoclonal B-cell lymphocytosis; however, she did not meet the diagnostic criteria due 
to the presence of chronic infection [16]. Monoclonal B-cell lymphocytosis is considered a precursor condition to chronic lymphocytic 
leukemia similar to monoclonal gammopathy of undetermined significant (MGUS) is a precursor condition to multiple myeloma [17, 
18]. Evidence suggests that precursor conditions such as MGUS which were initially thought to not have clinical implications are 
associated with increased rates of adverse skeletal events [19]. 
Our patient had a clear history of bisphosphonate-use and met the established criteria for MRONJ. However, her bisphosphonate 
use was limited to the oral bisphosphonate agent alendronate. Nitrogen-containing bisphosphontes such as alendronate, have been 
shown to trigger the release of pro-inflammatory mediators such as IL-6 and TNFa from osteoclasts. An in vivo study demonstrated 
bisphosphonate-treated osteoclasts survive longer than untreated osteoclasts as they are not subject to the cytotoxic effects of natural 
killer cells. The longer survival time may contribute to chronic inflammation in areas of bone turnover [20]. A large retrospective study 
of patients with chronic oral bisphosphonate therapy identified a low prevalence of MRONJ at 0.10% [21]. Other factors identified to 
increase the risk of MRONJ with oral bisphosphonate-use includes dental extraction, smoking, poorly-controlled diabetes, athero-
sclerosis, and steroid-use [22]. The additional risk factors for our patient only included history of dental extractions. Given the low 
prevalence of MRONJ with oral bisphosphonates and case reports that have implicated medications associated with iatrogenic lym-
phoproliferative disorders in MRONJ, is it unclear how our patient’s undiagnosed lymphoproliferative disorder may have contributed 
to her development of stage III MRONJ. Of note, the plasmocytic infiltration was seen outside of the area of necrotic bone and was 
included in the specimen due to segmental resection. In a review of margin analysis for MRONJ, Qaisi and Montague [23] discuss the 
need for representative samples of the resected bone to evaluate for underlying pathology contributing to bone destruction. In 
addition, there is difficulty in establishing a clear margin or additional pathologic processes with pathology specimens from conser-
vative debridements [23]. It is possible in our case the association of the clonal population in the MRONJ resection specimen was 
serendipitous and unrelated to her MRONJ progression. If so, the treatment allowed her to obtain a diagnosis before the manifestation 
of symptoms and enter active surveillance to monitor for transformation. However, there is evidence in the form of case series and case 
reports reviewed to suggest that lymphoproliferative disorders may play a yet undermined role in some forms of MRONJ. MRONJ in 
the setting immunosuppressant agents could represent an intramedullary manifestation of iatrogenic immunodeficiency-associated 
lymphoproliferative disorders. In much the same way that intravenous and oral bisphosphonate regimens have different risk pro-
files for the development of MRONJ, it could be that different forms of lymphoproliferative disorders factor differently into the MRONJ 
scenario [2,24]. Additional research is needed to elucidate possible interplay between lymphoproliferative disorders and osteonecrosis 
of the jaw. 
Fig. 6. Fluoresence In-Situ Hybridization of bone marrow biopsy demonstrating positive deletion of RB1.  
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A)                                                                 B)
C)
Fig. 7. Post-Operative Photos A) Worms-eye view of extraoral scar from mandibular resection B) Intraoral view of mandibular resection site C) 
Intraoral view of healed orocutaneous fistula site. 
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